BioSpace News Archive

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it plans to advance SAGE-718, a novel, first-in-class, oxysterol-based positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors, to a Phase 2 placebo-controlled clinical trial in patients with Huntington’s disease (HD).

Maintenance treatment with CC-486 resulted in a significant improvement in overall survival compared with placebo for front-line AML patients

SullivanCotter, the nation’s leading independent consulting firm in the assessment and development of total rewards programs and workforce solutions for the health care industry and not-for-profit sector, welcomes new Principal, Amber Duncan.

Kiniksa Pharmaceuticals, Ltd. announced that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California.

Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced the appointment of Mark McCamish, MD, Ph.D. to its board of directors, effective immediately..

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease

Navigen, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for the initiation of a Phase I study in healthy volunteers to test the safety, tolerability, and pharmacokinetics of its D-Peptide HIV entry inhibitor, CPT31..

Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone Pain

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that it will host a NASH Commercial Day for investors on Monday, December 16, 2019 from 9:00 a.m. to 12:30 p.m. ET in New York City..

RAPT Therapeutics, Inc. announced that Mary Ann Gray, Ph.D., President of Gray Strategic Advisors, LLC, has joined its Board of Directors.